Is AstraZeneca PLC a good dividend stock?

AstraZeneca PLC (AZN) is a dividend-paying stock with a current dividend yield of 3.17%. Review its dividend history, payout consistency and growth to judge whether it fits your income strategy.

What is AZN's dividend yield?

The dividend yield for AZN stock is currently 3.17%.

How much does AZN pay in dividends per year?

AstraZeneca PLC pays an annual dividend of $5.3730 per share over the trailing twelve months.

How often does AZN pay dividends?

AZN stock pays dividends bi-annually.

Is AZN's dividend growing?

AstraZeneca PLC's 3-year dividend CAGR is 23.68%.

AZN Stock Price, Chart, Stats & News

AstraZeneca PLC

Save

Overview Dividend safety Dividends Fundamentals

AstraZeneca PLC (AZN) is a dividend-paying stock with a current dividend yield of 3.17% as of Jul 21, 2026. It pays $5.37 per share over the trailing twelve months and distributes bi-annually. Its dividend has grown at a 14.09% 5-year compound annual rate.

–

Market cap

25.50x

Current P/E

18.38x

Forward P/E

3.17%

Dividend yield

$5.37

AZN dividend

Dividend safety

Moderate

Dividend coverage is moderate for AZN — it pays out about 81% of earnings.

See the safety analysis

AZN chart

Loading chart...

Fundamentals

Gross margin	81.90%
Operating margin	23.40%
Pretax margin	21.11%
Net margin	17.41%
Effective tax rate	17.49%
ROA	8.96%
ROE	22.68%
D/E	0.61x
Interest coverage ratio	8.11x

All financials

AZN valuation

P/E	25.50x
P/S	2.49x
P/B	3.00x
P/CF	9.96x
P/FCF	13.82x
P/OCF	9.96x
PEG	1.60x
EV multiple	6.16x

About

Health care

Sector

Drug Manufacturers - General

Industry

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris.